Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811330 | 0.96 | CTSL (0.42) | RORCCTSLCTSBCTSSCTSK | |
| SCHEMBL3834753 | 0.91 | CTSL (0.52) | RORCCTSLCTSBCTSSCTSK | |
| SCHEMBL3810189 | 0.91 | CTSL (0.52) | RORCCTSLCTSBCTSSCTSK | |
| SCHEMBL3810449 | 0.90 | RORC (0.46) | RORCCTSLCTSBCTSSCTSK | |
| SCHEMBL3816173 | 0.89 | LMNA (0.44) | CTSLCTSBCTSSCTSKCTSC | |
| SCHEMBL3810213 | 0.87 | PGR (0.42) | RORCCTSLCTSBCTSSCTSK | |
| SCHEMBL3806486 | 0.87 | CTSL (0.53) | RORCCTSLCTSBCTSSCTSK | |
| SCHEMBL3810220 | 0.86 | USP30 (0.42) | CTSLCTSBCTSSCTSKCTSC | |
| SCHEMBL3811481 | 0.86 | CTSL (0.42) | RORCCTSLCTSBCTSSCTSK | |
| SCHEMBL3815727 | 0.85 | CTSL (0.42) | RORCCTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | CTSF, CTSZ, CTSG | RORC 1662/4885CTSL 9/4885CTSB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.